Although the aberrant expression of DUX4 has been predominantly studied in the context of FSHD, recent studies have demonstrated that DUX4 is ectopically expressed in various cancers and plays a critical role in tumor progression, immune evasion, and therapy resistance. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.